Is Sigumir FDA approved?
No. This profile records Sigumir as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
Healing CATEGORY
Sigumir
THE JOINT REBUILDER
Cartilage Peptide Complex
Sigumir is a cartilage-derived bioregulator peptide that supports joint health and cartilage regeneration. It works by influencing gene expression in chondrocytes (cartilage cells) to boost collagen and proteoglycan production while reducing inflammatory enzymes that break down cartilage. It's particularly useful for osteoarthritis, joint injuries, and age-related cartilage degeneration.
Sigumir
Sigumir
Sigumir
Sigumir Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
Not FDA approved · research use only
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
1 research sources
CONTENT UPDATED
May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Sigumir
What dose does The Peptide App Clinical Team recommend for Sigumir?
Dose: 10 mg daily (oral or subcutaneous).
MORE CONTEXT ›
Schedule: daily. Cycle: 10-30 days on, 4 months off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Sigumir guide?
This guide links to 1 curated or current research sources.
MORE CONTEXT ›
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Studied Effects & Mechanisms
Chondrocyte Gene Activation
Upregulates type II collagen and aggrecan genes
MMP Inhibition
Suppresses enzymes that break down cartilage
Growth Factor Support
Increases IGF-1 and TGF-β for cartilage repair
Synovial Support
Enhances synovial fluid and lubricin production
Those with osteoarthritis
People with chronic joint pain
Athletes with cartilage injuries
Anyone with age-related joint degeneration
Those wanting to protect joint health proactively
Sigumir Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.
RESEARCH REFERENCES